Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase<scp>III</scp>trialsEric L. Simpson, Kristian Reich, Thomas Bieber et al.|British Journal of Dermatology|2020Cited by 389
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitisEric L. Simpson, Amy S. Paller, Robert Bissonnette et al.|Journal of the American Academy of Dermatology|2020Cited by 181
Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)Joanne R Chalmers, Natasha K Rogers, Kim S Thomas et al.|British Journal of Dermatology|2018Cited by 160
Development of the alopecia areata scale for clinical use: Results of an academic–industry collaborative effortBrett King, Maryanne M. Senna, Natasha Atanaskova Mesinkovska et al.|Journal of the American Academy of Dermatology|2021Cited by 79
Measuring Atopic Eczema Control and Itch Intensity in Clinical PracticeYael A. Leshem, Joanne R Chalmers, Christian Apfelbacher et al.|JAMA Dermatology|2022Cited by 36